IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 for the treatment of patients with generalized myasthenia gravis.
We believe that IGM-2644 with its 10 binding units for CD38 may bind to CD38 expressing cells more strongly (higher avidity) than an IgG bispecific antibody with only one or two binding units for CD38. CD38 is expressed on plasma cells which are the source of autoreactive antibodies in several autoimmune diseases.